The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

ClinicalTCCL Archive

NCI CTEP-Approved Trials for the Month of November

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.

Phase II

9598: A Phase II Therapeutic Trial of the Use of Dabrafenib and Trametinib in Patients with BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease. National Institutes of Health; Estrada-Veras, Juvianee Ibrahim. (301) 594-2952

9653: Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients with Advanced or Unresectable Urothelial Carcinoma of the Bladder. University of California Davis Comprehensive Cancer Center P2C; Sadeghi, Sarmad. (323) 865-0553

9880: Haploidentical Donor Natural Killer (NK) Cell Infusion with Subcutaneous Recombinant Human IL-15 (rhIL-15) in Adults with Refractory or Relapsed Acute Myelogenous Leukemia. University of Minnesota Medical Center-Fairview; Miller, Jeffrey Steven (612) 624-0123

NRG-BN001: Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma. NRG Oncology; Mehta, Minesh P. (410) 328-9629

NRG-HN002: A Randomized Phase II Trial for Patients with p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer. NRG Oncology; Yom, Sue Sun (415) 353-7410

Other Phases

A151315: An Analysis of Baseline Serum NTx and BAP as Independent Predictors of Overall Survival and Risk of SREs. Alliance for Clinical Trials in Oncology; Saylor, Philip James. (617) 643-1763

ECOG-E2197F-ECOG-ICSC: Tumor MicroEnvironment of Metastasis (TMEM) and MenaCalc: Validation as Prognostic and Predictive Markers. ECOG-ACRIN Cancer Research Group; Sparano, Joseph Anthony (718) 904-2555

YOU MAY BE INTERESTED IN

Clinical

Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

By Claire Marie Porter and Sara Willa Ernst
Guest Editorial

My introduction to, and lessons learned from, Rick Pazdur

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
By Mikkael A. Sekeres
Sponsored

Meeting the moment: ASCO GI Cancers Symposium delivers insights and collaboration

When it comes to fighting cancer today, collaboration is key. At a time when funding is uncertain, yet innovative breakthroughs are accelerating every day, it’s more important than ever for oncologists, scientists, academic researchers, and community physicians, to come together to share knowledge and gain insights about the forefront of cancer research.
By The American Society of Clinical Oncology

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account